Q2 2026 saw 17.8% sales growth at CER and a 33.3% rise in business EPS, driven by strong pharma launches and Dupixent. Upgraded 2026 guidance expects ~10% sales growth at CER, with business EPS outpacing sales. Significant pipeline progress and capital returns were reported.Original document: Sanof…
Q2 2026 saw 17.8% sales growth at CER and a 33.3% rise in business EPS, driven by strong pharma launches and Dupixent. Upgraded 2026 guidance expects ~10% sales growth at CER, with business EPS outpacing sales. Significant pipeline progress and capital returns were reported.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
